[The pharmacokinetic modification of mutagenesis]

Area of Science:

• Pharmacology
• Toxicology
• Genetics

Background:

• Antitumor and antituberculous agents can exhibit mutagenic activity.
• Understanding drug-induced mutations is crucial for patient safety.
• Isoniazid is a key drug in tuberculosis treatment.

Purpose of the Study:

• To evaluate the mutagenic activity of specific antitumor drugs and isoniazid.
• To determine if auxiliary substances can modify the mutagenic effects of these drugs.
• To investigate the pharmacokinetic mechanisms underlying these modifications.

Main Methods:

• Mutagenesis assays in Drosophila, mammalian, and human cell models.
• Pharmacokinetic analysis to examine drug formulation effects.
• Comparative studies of drug formulations with and without auxiliaries.

Main Results:

• Mutagenic effects of the studied drugs were confirmed.
• Auxiliary substances significantly modified the mutagenic activity of the drugs.
• Pharmacokinetic techniques elucidated the mechanisms of modification.

Conclusions:

• Drug formulations, including auxiliaries, play a critical role in modulating mutagenicity.
• Pharmacokinetic studies are essential for understanding drug-induced genetic toxicity.
• Further research into drug-auxiliary interactions is warranted to optimize therapeutic safety.